Husseini Manji

CEO, Science For Minds LLC, Johnson & Johnson

As Global Head for Johnson & Johnson Science for Minds, Husseini Manji, MD, FRCPC leads the new initiative aimed at addressing the significant unmet needs of patients with neuropsychiatric and neurodegenerative disorders. His team is working to catalyze the development of novel and improved solutions for our patients worldwide with a focus on serious mental health disorders, especially those affecting youth; dementia; and innovative digital solutions/technologies. Previously, Dr. Manji was Global Therapeutic Head for Neuroscience at Janssen Research & Development, one of the Pharmaceutical Companies of Johnson & Johnson. Prior to joining J&J, Dr. Manji was Chief of the Laboratory of Molecular Pathophysiology at the National Institutes of Health (NIH) and Director of the NIH Mood and Anxiety Disorders Program, the largest of its kind in the world. His research has helped to conceptualize neuropsychiatric conditions as genetically influenced disorders of synapses and circuits and has prompted the investigation of novel therapeutics for patients. Dr. Manji is a Visiting Professor at both Duke University and at Oxford University.

Suscribirse a las actualizaciones

Una actualización semanal de lo que hay en la Agenda Global

© 2022 World Economic Forum

Política de privacidad y normas de uso